Gastric cancer – the recognition of a chemosensitive tumour

Cunningham, David A.

doi:10.1038/bjc.1988.292

Cited by 16 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor proliferation is one of the important factors in determining the response of tumors to a variety of anti-cancer agents (Valeriote and van Putten, 1975) although this has been challenged (Tannock, 1978). Gastric carcinoma is supposed to be more chemosensitive than colorectal carcinoma (Cunningham, 1988). However, we observed significantly lower Ki-67 indices in gastric than in colorectal cancers.…”

Section: Discussioncontrasting

confidence: 55%

Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki‐67 immunostaining

Porschen¹,

Kriegel²,

Langen³

et al. 1991

Intl Journal of Cancer

View full text Add to dashboard Cite

The monoclonal antibody (MAb) Ki-67, which is directed against a proliferation-associated nuclear antigen, was used to measure tumor proliferation in 165 carcinomas of the esophagus, stomach, colon and rectum with an indirect immunoperoxidase technique. The percentage of Ki-67-positive tumor cells (Ki-67 index) was evaluated with the point-counting method. The Ki-67 index in gastric cancers (mean, 24.8%; standard deviation, 11.1%) was significantly lower than in tumors of the esophagus (35.7 +/- 12.6%), colon (37.6 +/- 15.2%), and rectum (34.3 +/- 16.4%). A wide range of the Ki-67 index (5.9-75.3%) could be observed within the various tumor types. In recurrent colorectal carcinomas, the Ki-67 index significantly increased to 51.9%. The Ki-67 index was independent of pathologic (e.g., TNM-stage, grading, tumor volume, tumor site) and clinical variables (age and gender of the patients). A marked heterogeneity of Ki-67 expression within different tumor stages was noted. Statistically significant regional variations in tumor proliferation existed between different areas within the same tumor.

show abstract

Section: Discussioncontrasting

confidence: 55%

Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki‐67 immunostaining

Porschen¹,

Kriegel²,

Langen³

et al. 1991

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Selection of appropriate therapy for the patient with metastatic gastric cancer can pose exceedingly difficult challenges. Although often effective, the survival benefit to systemic chemotherapy and other nonsurgical modalities is modest at best [8][9][10][11]. Traditional surgical literature has advocated several theoretical benefits to palliative resection for patients with stage IV gastric cancer [3,5,6,12].…”

Section: Discussionmentioning

confidence: 99%

Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?

Lim

Muhs

Marcus

et al. 2007

Journal of Surgical Oncology

View full text Add to dashboard Cite

Long-term survival for patients with stage IV gastric cancer who are managed with surgical resection is achievable. Patient specific variables including East Asian race and age less than 60 years appear to be associated with prolonged survival when assessed by comparison of means, Kaplan-Meier analysis, and univariate regression analysis. However, multivariate regression analysis failed to demonstrate these factors as independent predictors of improved outcome. In conclusion, highly selected acceptable risk surgical candidates with stage IV gastric cancer should be considered for management with surgical resection in clinically appropriate scenarios.

show abstract

“…surgical resection and radiation. Recently it has generally been recognized that gastric cancers show high sensitivity to chemotherapy [9]. In therapeutic studies conducted on single agents in 14 or more gastric cancer patients who had undergone no prior therapy, a response rate (CR + PR cases according to the WHO criteria [8]) of 15% or higher was reported for 5-FU, epirubicin, doxorubicin, cisplatin, MMC, BCNU and etoposide [5].…”

Section: Discussionmentioning

confidence: 99%

Phase II Study of Combined Administration of 5-Fluorouracil, Epirubicin and Mitomycin-C by Hepatic Artery Infusion in Patients with Liver Metastases of Gastric Cancer

et al. 1999

View full text Add to dashboard Cite

This multicenter phase II study evaluated the efficacy of the FEM regimen (5-fluorouracil 333 mg/m² each week, epirubicin 30 mg/m² once every 4 weeks and mitomycin-C 2.7 mg/m² once every 2 weeks) administered by hepatic artery infusion (HAI) for unresectable hepatic metastases of gastric cancer. The response rates were 55.6% (complete response: 3, partial response: 32, no change: 21, progressive disease: 7/63) and the mean 50% survival was 10.5 months. Most responders died due to the progression of extrahepatic lesions. HAI of the FEM regimen induced a high response rate in patients with hepatic metastases of gastric cancer, and the prognosis-determining factor was the existence of extrahepatic lesions in many patients.

show abstract

Gastric cancer – the recognition of a chemosensitive tumour

Cited by 16 publications

References 32 publications

Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki‐67 immunostaining

Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki‐67 immunostaining

Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?

Phase II Study of Combined Administration of 5-Fluorouracil, Epirubicin and Mitomycin-C by Hepatic Artery Infusion in Patients with Liver Metastases of Gastric Cancer

Contact Info

Product

Resources

About